1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. Y-MABS THERAPEUTICS INC

Y-Mabs Therapeutics Inc XNAS: YMAB

Y-Mabs Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

5.00 0.08 (1.63%)

71.88% Fall from 52W High

1.1M XNAS Volume

High volume today

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Y-Mabs Therapeutics Inc Key Metrics

Select

Market Capitalization

Below industry Median
226.1

PE TTM

Negative PE TTM
-7.6

PEG TTM

Below industry Median
0.2

Price to Book

Below industry Median
2.4

Institutional holding current Qtr %

Below industry Median
57.4

Revenue Growth Qtr YoY %

Below industry Median
13.4

Operating Revenue growth TTM %

Below industry Median
3.4

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-587.2

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-38.5

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-35.6

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-48.2
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
11.1 / 100
Valuation Score
Expensive Valuation
18.3 / 100
Momentum Score
Technically Bearish
25.2 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
17
1Yr Price target upside is 240%
10 analysts

10

S

13

W

0

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Y-Mabs Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26050100150Actual RevenueAvg. Estimate
Hit

Y-Mabs Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-0.7
Avg. Estimate
-1
Low Estimate
-1.1
High Estimate
-0.8
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 43.3% in FY25

Consensus Recommendation

10 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Strong Sell1Hold1Buy7Strong Buy

The consensus recommendation from 10 analysts for Y-Mabs Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Y-Mabs Therapeutics Inc Stock Analysis

Y-Mabs Therapeutics Inc stock analysis with key metrics, changes, and trends.

Y-Mabs Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$87.68 M3.38%positive

Annual Revenue rose 3.38%, in the last year to $87.68 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$29.67 M38.45%negative

Annual Net Profit fell 38.45% in the last year to $29.67 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio-7.62-negative

Price to Earning Ratio is -7.62, which is negative.

Stock Price$5.00-69.19%negative

Stock Price fell 69.19% and underperformed its sector by 78.26% in the past year.

Quarterly Revenue$26.5 M13.41%positive

Quarterly Revenue rose 13.41% YoY to $26.5 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$6.79 M587.25%negative

Quarterly Net profit fell 587.25% YoY to $6.79 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Mutual Fund Holding36.05 %-0.76%negative

Mutual Fund Holding decreased by 0.76% in the last quarter to 36.05.

Promoter Share Holding1.61 %0.44%positive

Promoter Share Holding increased by 0.44% in the most recent quarter to 1.61%.

Institutional Holding57.44 %0%neutral

Institutional Holding remained the same in the last quarter at 57.44%.

VIEW LESS


Loading data..

Y-Mabs Therapeutics Inc - Company Profile

What does Y-Mabs Therapeutics Inc do?

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Y-Mabs Therapeutics Inc Management structure

All Gross Remunerations are in USD
Ms. Sue Smith
Senior Vice President and Chief Commercial Officer
-
2025
Gross Remuneration
Year
Mr. Doug Gentilcore
Senior Vice President, Danyelza Business
-
2025
Gross Remuneration
Year
Ms. Natalie Tucker
Senior Vice President, Radiopharmaceutical Business Head
-
2025
Gross Remuneration
Year

Y-Mabs Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Mary A. Tagliaferri, M.D.
Director
-
2024
Gross Remuneration
Year
Dr. Gerard Ber, PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. David N. Gill
Independent Director
-
2024
Gross Remuneration
Year
Mr. Johan Wedell-Wedellsborg
Independent Director
-
2024
Gross Remuneration
Year
Dr. James I. Healy, M.D.,PhD
Chairman of the Board
-
2024
Gross Remuneration
Year
Ms. Laura J. Hamill
Independent Director
-
2024
Gross Remuneration
Year

Y-Mabs Therapeutics Inc FAQ

How is Y-Mabs Therapeutics Inc today?
Y-Mabs Therapeutics Inc today is trading in the green, and is up by 1.63% at 5.00.
Y-Mabs Therapeutics Inc is currently trading up 1.63% on an intraday basis. In the past week the stock rose 7.07%. stock has been down -39.61% in the past quarter and fell -69.19% in the past year. You can view this in the overview section.